Dissociation of immunologic and virologic responses to highly active antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 23, Issue 4, 2000, Pages 314-320

  Fessel, W Jeffrey ^a,d   Krowka, John F ^b   Sheppard, Haynes W ^b   Gesner, Marianne ^b   Tongson, Sebastian ^b   Weinstein, Samuel ^b   Ascher, Michael ^b   Kwok, Shirley ^c   Christopherson, Cindy ^c  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

^c ROCHE MOLECULAR SYSTEMS   (United States)

^d KaiserPermanente Medical Center   (United States)

Author keywords

HAART; HIV; Immunologic response; Virologic response

Indexed keywords

ANTIRETROVIRUS AGENT; BETA 2 MICROGLOBULIN; CD4 ANTIGEN; CD8 ANTIGEN; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEOPTERIN; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; LYMPHOCYTE COUNT; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0034176394     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200004010-00005     Document Type: Article

References (37)

1. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997;349:1443-5.
2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
3. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-17.
4. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in patients with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
5. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
6. Fessel WJ, Hurley LB. Outcomes of triple therapy that included a protease inhibitor among 2139 patients [abstract 145]. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, 1998.
7. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998;351:723-4.
8. Piketty C, Castiel P, Belec L, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998;12:745-50.
9. Levitz SM. Improvement in CD4+ cell counts despite persistently detectable HIV load. N Engl J Med 1998;338:1074-5.
10. Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 1999;13:669-76.
11. Barreiro PM, Dona MC, Castilla J, Soriano V. Patterns of response (CD4 count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy. AIDS 1999;13:525-6.
12. Mellors JW, Rinaldo CT, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
13. Marschner IC, Collier AC, Coombs RW, D'Aquila RD, DeGruttola VD. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998;177:40-7.
14. Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W. The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T cell levels. AIDS 1993;7:1159-66.
15. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994;32:292-300.
16. Dewar RL, Highbarger HC, Sarmiento MD, et al. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis 1994; 170:1172-9.
17. Michael NL, Herman SA, Kwok S, et al. Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1, and the performance of an improved AMPLICOR HIV-1 MONITOR test on diverse subtypes. J Clin Microbiol 1999;37:2557-2563.
18. Christopherson C, Kidane Y, Conway B, et al. A PCR based assay to quantify HIV-1 DNA in peripheral blood mononuclear cells. J Clin Microbiol 2000;38:630-4.
19. Christopherson C, Mulder J, Conway B, et al. Evolution of HIV-1 proviral DNA in patients with undetectable RNA [abstract]. 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., U.S.A., 1997.
20. Coombs RW Collier AC, Allain JP, et al. Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989;321:1626-31.
21. Fiscus SA, DeGruttola V, Gutpa P, et al. Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial. J Infect Dis 1995; 171:305-311.
22. Myers LE, McQuay LJ, Hollinger FB. Dilution assay statistics. J Clin Microbiol 1994;32:732-9.
23. Piatak M, Luk KC, Saag MS, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993;259:1749-54.
24. Andreoni M, Sarmati L, Ercoli L, et al. Correlation between changes in plasma HIV RNA levels and plasma infectivity in response to antiretroviral therapy. AIDS Res Human Retroviruses 1997;13:555-61.
25. Flexner C. HIV-protease inhibitors. N Engl J Med 1998;338:1281-92.
26. Panther LA, Coombs RW, Aung SA, dela Rosa C, Gretch, Corey L. Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro. J Med Virol 1999;58:165-73.
27. Faye A, Race E, Obry V, et al. Viral fitness in patients with discordant CD4 and plasma HIV RNA evolution following protease inhibitor failure [abstract 331]. 6th Conference on Retroviruses and Opportunistic Infection, Chicago, 1999.
28. Lyles CM, Graham NMH, Astemborski J, et al. Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men. Eur J Epi 1999;15:99-108.
29. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997;387:188-91.
30. Staszewsku S, Miller V, Sabin C, et al. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS 1999;13:951-6.
31. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998;4:208-14.
32. Anderson RW, Ascher MS, Sheppard HW. Direct HIV cytopathicity cannot account for CD4 decline in AIDS in the presence of homeostasis. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:245-52.
33. Hellerstein MK, McCune JM. T Cell turnover in HIV-1 disease. Immunity 1998;7:583-589.
34. Weiss L, Ancuta P, Girard PM, et al. Restoration of normal interleukin-2 production by CD4+ T Cells of human immunodeficiency virus-infected patients after 9 months of highly active antiretroviral therapy. Infect Dis 1999;180:1057-63.
35. Kaufmann GR, Zaunders JJ, Cunningham P, Cooper DA. Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA. AIDS Res Hum Retroviruses 1999;15:963-72.
36. Sousa AE, Chaves AF, Doroana M, Antunes F, Victorino RM. Early reduction of the over-expression of CD40L, OX40 and Fas on T cells in HIV-1 infection during triple anti-retroviral therapy: possible implications for lymphocyte traffic and functional recovery. Clin Exp Immunol 1999 May;116:307-15.
37. Bucy RP, Hockett RD, Derdeyn CA, et al. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999;103:1391-8.